ArticleThe Journal of precision medicine2018
The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.
Article in The Journal of precision medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Trial
- Strengthening supply chains for pathogen genomic surveillance in Asia.BMJ global health · 2026Article
- Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study.HemaSphere · 2023Article
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- seGMM: A New Tool for Gender Determination From Massively Parallel Sequencing Data.Frontiers in genetics · 2022Article
- Opportunity of Next-Generation Sequencing-Based Short Tandem Repeat System for Tumor Source Identification.Frontiers in oncology · 2022Article
- The practice of genomic medicine: A delineation of the process and its governing principles.Frontiers in medicine · 2022Article
- FINDER: an automated software package to annotate eukaryotic genes from RNA-Seq data and associated protein sequences.BMC bioinformatics · 2021Article
- Availability and funding of clinical genomic sequencing globally.BMJ global health · 2021Review
- Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation.JAMA · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The market for next-generation sequencing technologies (NGS) has grown dramatically. Health care decision-makers need empirical evidence on market growth and future trends in order to develop appropriate strategies and policies, but little has been published about the nature and size of these trends. We provide a snapshot of market trends through 2020. We found rapid growth of clinical NGS - the global clinical NGS services market was $2.2 billion in 2015 and is forecast to reach $7.7 billion by 2020. The reproductive health NGS test market is the largest market followed by the oncology NGS test market. The largest market is for tests that sequence >50 genes but not the entire exome or genome. Markets are growing rapidly in countries outside of the US. Despite rapid NGS test growth, there are a number of key issues that will need to be addressed to facilitate appropriate future growth.
Identifiers
32149190PMC7059995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.